カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のオーファン疾患治療市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Orphan Indication Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19492）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19492
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：101
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のオーファン疾患治療市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

オーファン疾患治療市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のオーファン疾患治療の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

オーファン疾患治療市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・生物製剤、非生物製剤

用途別セグメントは次のように区分されます。
・病院調剤、小売調剤、通信販売

世界のオーファン疾患治療市場の主要な市場プレーヤーは以下のとおりです。
・Bristol-Myers Squibb、Roche、Novartis、Johnson & Johnson、Pfizer、Amgen、Sanofi、AstraZeneca、Takeda、Vertex Pharmaceuticals、AbbVie、Biogen、Eli Lilly

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、オーファン疾患治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なオーファン疾患治療メーカーの企業概要、2019年～2022年までのオーファン疾患治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なオーファン疾患治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別オーファン疾患治療の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのオーファン疾患治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのオーファン疾患治療市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびオーファン疾患治療の産業チェーンを掲載しています。
・第13、14、15章では、オーファン疾患治療の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- オーファン疾患治療の概要
- 種類別分析（2017年vs2021年vs2028年）：生物製剤、非生物製剤
- 用途別分析（2017年vs2021年vs2028年）：病院調剤、小売調剤、通信販売
- 世界のオーファン疾患治療市場規模・予測
- 世界のオーファン疾患治療生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Bristol-Myers Squibb、Roche、Novartis、Johnson & Johnson、Pfizer、Amgen、Sanofi、AstraZeneca、Takeda、Vertex Pharmaceuticals、AbbVie、Biogen、Eli Lilly
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：生物製剤、非生物製剤
・用途別分析2017年-2028年：病院調剤、小売調剤、通信販売
・オーファン疾患治療の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・オーファン疾患治療のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・オーファン疾患治療のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・オーファン疾患治療の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・オーファン疾患治療の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Orphan Indication Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Orphan Indication Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacy accounting for % of the Orphan Indication Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Biologics segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Orphan Indication Treatment include Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Orphan Indication Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Biologics
Non-Biologics
Market segment by Application can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Sales
The key market players for global Orphan Indication Treatment market are listed below:
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Orphan Indication Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Orphan Indication Treatment, with price, sales, revenue and global market share of Orphan Indication Treatment from 2019 to 2022.
Chapter 3, the Orphan Indication Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Orphan Indication Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Orphan Indication Treatment market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Orphan Indication Treatment.
Chapter 13, 14, and 15, to describe Orphan Indication Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Orphan Indication Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Orphan Indication Treatment Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Biologics
1.2.3 Non-Biologics
1.3 Market Analysis by Application
1.3.1 Overview: Global Orphan Indication Treatment Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Sales
1.4 Global Orphan Indication Treatment Market Size & Forecast
1.4.1 Global Orphan Indication Treatment Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Orphan Indication Treatment Sales in Volume (2017-2028)
1.4.3 Global Orphan Indication Treatment Price (2017-2028)
1.5 Global Orphan Indication Treatment Production Capacity Analysis
1.5.1 Global Orphan Indication Treatment Total Production Capacity (2017-2028)
1.5.2 Global Orphan Indication Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Orphan Indication Treatment Market Drivers
1.6.2 Orphan Indication Treatment Market Restraints
1.6.3 Orphan Indication Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Orphan Indication Treatment Product and Services
2.1.4 Bristol-Myers Squibb Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Orphan Indication Treatment Product and Services
2.2.4 Roche Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Orphan Indication Treatment Product and Services
2.3.4 Novartis Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business
2.4.3 Johnson & Johnson Orphan Indication Treatment Product and Services
2.4.4 Johnson & Johnson Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Orphan Indication Treatment Product and Services
2.5.4 Pfizer Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Amgen
2.6.1 Amgen Details
2.6.2 Amgen Major Business
2.6.3 Amgen Orphan Indication Treatment Product and Services
2.6.4 Amgen Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Orphan Indication Treatment Product and Services
2.7.4 Sanofi Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Orphan Indication Treatment Product and Services
2.8.4 AstraZeneca Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business
2.9.3 Takeda Orphan Indication Treatment Product and Services
2.9.4 Takeda Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Vertex Pharmaceuticals
2.10.1 Vertex Pharmaceuticals Details
2.10.2 Vertex Pharmaceuticals Major Business
2.10.3 Vertex Pharmaceuticals Orphan Indication Treatment Product and Services
2.10.4 Vertex Pharmaceuticals Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Orphan Indication Treatment Product and Services
2.11.4 AbbVie Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Biogen
2.12.1 Biogen Details
2.12.2 Biogen Major Business
2.12.3 Biogen Orphan Indication Treatment Product and Services
2.12.4 Biogen Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Eli Lilly
2.13.1 Eli Lilly Details
2.13.2 Eli Lilly Major Business
2.13.3 Eli Lilly Orphan Indication Treatment Product and Services
2.13.4 Eli Lilly Orphan Indication Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Orphan Indication Treatment Breakdown Data by Manufacturer
3.1 Global Orphan Indication Treatment Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Orphan Indication Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Orphan Indication Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Orphan Indication Treatment Manufacturer Market Share in 2021
3.4.2 Top 6 Orphan Indication Treatment Manufacturer Market Share in 2021
3.5 Global Orphan Indication Treatment Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Orphan Indication Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Orphan Indication Treatment Market Size by Region
4.1.1 Global Orphan Indication Treatment Sales in Volume by Region (2017-2028)
4.1.2 Global Orphan Indication Treatment Revenue by Region (2017-2028)
4.2 North America Orphan Indication Treatment Revenue (2017-2028)
4.3 Europe Orphan Indication Treatment Revenue (2017-2028)
4.4 Asia-Pacific Orphan Indication Treatment Revenue (2017-2028)
4.5 South America Orphan Indication Treatment Revenue (2017-2028)
4.6 Middle East and Africa Orphan Indication Treatment Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Orphan Indication Treatment Sales in Volume by Type (2017-2028)
5.2 Global Orphan Indication Treatment Revenue by Type (2017-2028)
5.3 Global Orphan Indication Treatment Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Orphan Indication Treatment Sales in Volume by Application (2017-2028)
6.2 Global Orphan Indication Treatment Revenue by Application (2017-2028)
6.3 Global Orphan Indication Treatment Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Orphan Indication Treatment Sales by Type (2017-2028)
7.2 North America Orphan Indication Treatment Sales by Application (2017-2028)
7.3 North America Orphan Indication Treatment Market Size by Country
7.3.1 North America Orphan Indication Treatment Sales in Volume by Country (2017-2028)
7.3.2 North America Orphan Indication Treatment Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Orphan Indication Treatment Sales by Type (2017-2028)
8.2 Europe Orphan Indication Treatment Sales by Application (2017-2028)
8.3 Europe Orphan Indication Treatment Market Size by Country
8.3.1 Europe Orphan Indication Treatment Sales in Volume by Country (2017-2028)
8.3.2 Europe Orphan Indication Treatment Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Orphan Indication Treatment Sales by Type (2017-2028)
9.2 Asia-Pacific Orphan Indication Treatment Sales by Application (2017-2028)
9.3 Asia-Pacific Orphan Indication Treatment Market Size by Region
9.3.1 Asia-Pacific Orphan Indication Treatment Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Orphan Indication Treatment Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Orphan Indication Treatment Sales by Type (2017-2028)
10.2 South America Orphan Indication Treatment Sales by Application (2017-2028)
10.3 South America Orphan Indication Treatment Market Size by Country
10.3.1 South America Orphan Indication Treatment Sales in Volume by Country (2017-2028)
10.3.2 South America Orphan Indication Treatment Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Orphan Indication Treatment Sales by Type (2017-2028)
11.2 Middle East & Africa Orphan Indication Treatment Sales by Application (2017-2028)
11.3 Middle East & Africa Orphan Indication Treatment Market Size by Country
11.3.1 Middle East & Africa Orphan Indication Treatment Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Orphan Indication Treatment Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Orphan Indication Treatment and Key Manufacturers
12.2 Manufacturing Costs Percentage of Orphan Indication Treatment
12.3 Orphan Indication Treatment Production Process
12.4 Orphan Indication Treatment Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Orphan Indication Treatment Typical Distributors
13.3 Orphan Indication Treatment Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Orphan Indication Treatment Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Orphan Indication Treatment Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 4. Bristol-Myers Squibb Major Business
Table 5. Bristol-Myers Squibb Orphan Indication Treatment Product and Services
Table 6. Bristol-Myers Squibb Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Roche Basic Information, Manufacturing Base and Competitors
Table 8. Roche Major Business
Table 9. Roche Orphan Indication Treatment Product and Services
Table 10. Roche Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Novartis Basic Information, Manufacturing Base and Competitors
Table 12. Novartis Major Business
Table 13. Novartis Orphan Indication Treatment Product and Services
Table 14. Novartis Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 16. Johnson & Johnson Major Business
Table 17. Johnson & Johnson Orphan Indication Treatment Product and Services
Table 18. Johnson & Johnson Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer Orphan Indication Treatment Product and Services
Table 22. Pfizer Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Amgen Basic Information, Manufacturing Base and Competitors
Table 24. Amgen Major Business
Table 25. Amgen Orphan Indication Treatment Product and Services
Table 26. Amgen Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Sanofi Basic Information, Manufacturing Base and Competitors
Table 28. Sanofi Major Business
Table 29. Sanofi Orphan Indication Treatment Product and Services
Table 30. Sanofi Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 32. AstraZeneca Major Business
Table 33. AstraZeneca Orphan Indication Treatment Product and Services
Table 34. AstraZeneca Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Takeda Basic Information, Manufacturing Base and Competitors
Table 36. Takeda Major Business
Table 37. Takeda Orphan Indication Treatment Product and Services
Table 38. Takeda Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Vertex Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 40. Vertex Pharmaceuticals Major Business
Table 41. Vertex Pharmaceuticals Orphan Indication Treatment Product and Services
Table 42. Vertex Pharmaceuticals Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. AbbVie Basic Information, Manufacturing Base and Competitors
Table 44. AbbVie Major Business
Table 45. AbbVie Orphan Indication Treatment Product and Services
Table 46. AbbVie Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Biogen Basic Information, Manufacturing Base and Competitors
Table 48. Biogen Major Business
Table 49. Biogen Orphan Indication Treatment Product and Services
Table 50. Biogen Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 52. Eli Lilly Major Business
Table 53. Eli Lilly Orphan Indication Treatment Product and Services
Table 54. Eli Lilly Orphan Indication Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Global Orphan Indication Treatment Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 56. Global Orphan Indication Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 57. Market Position of Manufacturers in Orphan Indication Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 58. Global Orphan Indication Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 59. Head Office and Orphan Indication Treatment Production Site of Key Manufacturer
Table 60. Orphan Indication Treatment New Entrant and Capacity Expansion Plans
Table 61. Orphan Indication Treatment Mergers & Acquisitions in the Past Five Years
Table 62. Global Orphan Indication Treatment Sales by Region (2017-2022) & (K Units)
Table 63. Global Orphan Indication Treatment Sales by Region (2023-2028) & (K Units)
Table 64. Global Orphan Indication Treatment Revenue by Region (2017-2022) & (USD Million)
Table 65. Global Orphan Indication Treatment Revenue by Region (2023-2028) & (USD Million)
Table 66. Global Orphan Indication Treatment Sales by Type (2017-2022) & (K Units)
Table 67. Global Orphan Indication Treatment Sales by Type (2023-2028) & (K Units)
Table 68. Global Orphan Indication Treatment Revenue by Type (2017-2022) & (USD Million)
Table 69. Global Orphan Indication Treatment Revenue by Type (2023-2028) & (USD Million)
Table 70. Global Orphan Indication Treatment Price by Type (2017-2022) & (US$/Unit)
Table 71. Global Orphan Indication Treatment Price by Type (2023-2028) & (US$/Unit)
Table 72. Global Orphan Indication Treatment Sales by Application (2017-2022) & (K Units)
Table 73. Global Orphan Indication Treatment Sales by Application (2023-2028) & (K Units)
Table 74. Global Orphan Indication Treatment Revenue by Application (2017-2022) & (USD Million)
Table 75. Global Orphan Indication Treatment Revenue by Application (2023-2028) & (USD Million)
Table 76. Global Orphan Indication Treatment Price by Application (2017-2022) & (US$/Unit)
Table 77. Global Orphan Indication Treatment Price by Application (2023-2028) & (US$/Unit)
Table 78. North America Orphan Indication Treatment Sales by Country (2017-2022) & (K Units)
Table 79. North America Orphan Indication Treatment Sales by Country (2023-2028) & (K Units)
Table 80. North America Orphan Indication Treatment Revenue by Country (2017-2022) & (USD Million)
Table 81. North America Orphan Indication Treatment Revenue by Country (2023-2028) & (USD Million)
Table 82. North America Orphan Indication Treatment Sales by Type (2017-2022) & (K Units)
Table 83. North America Orphan Indication Treatment Sales by Type (2023-2028) & (K Units)
Table 84. North America Orphan Indication Treatment Sales by Application (2017-2022) & (K Units)
Table 85. North America Orphan Indication Treatment Sales by Application (2023-2028) & (K Units)
Table 86. Europe Orphan Indication Treatment Sales by Country (2017-2022) & (K Units)
Table 87. Europe Orphan Indication Treatment Sales by Country (2023-2028) & (K Units)
Table 88. Europe Orphan Indication Treatment Revenue by Country (2017-2022) & (USD Million)
Table 89. Europe Orphan Indication Treatment Revenue by Country (2023-2028) & (USD Million)
Table 90. Europe Orphan Indication Treatment Sales by Type (2017-2022) & (K Units)
Table 91. Europe Orphan Indication Treatment Sales by Type (2023-2028) & (K Units)
Table 92. Europe Orphan Indication Treatment Sales by Application (2017-2022) & (K Units)
Table 93. Europe Orphan Indication Treatment Sales by Application (2023-2028) & (K Units)
Table 94. Asia-Pacific Orphan Indication Treatment Sales by Region (2017-2022) & (K Units)
Table 95. Asia-Pacific Orphan Indication Treatment Sales by Region (2023-2028) & (K Units)
Table 96. Asia-Pacific Orphan Indication Treatment Revenue by Region (2017-2022) & (USD Million)
Table 97. Asia-Pacific Orphan Indication Treatment Revenue by Region (2023-2028) & (USD Million)
Table 98. Asia-Pacific Orphan Indication Treatment Sales by Type (2017-2022) & (K Units)
Table 99. Asia-Pacific Orphan Indication Treatment Sales by Type (2023-2028) & (K Units)
Table 100. Asia-Pacific Orphan Indication Treatment Sales by Application (2017-2022) & (K Units)
Table 101. Asia-Pacific Orphan Indication Treatment Sales by Application (2023-2028) & (K Units)
Table 102. South America Orphan Indication Treatment Sales by Country (2017-2022) & (K Units)
Table 103. South America Orphan Indication Treatment Sales by Country (2023-2028) & (K Units)
Table 104. South America Orphan Indication Treatment Revenue by Country (2017-2022) & (USD Million)
Table 105. South America Orphan Indication Treatment Revenue by Country (2023-2028) & (USD Million)
Table 106. South America Orphan Indication Treatment Sales by Type (2017-2022) & (K Units)
Table 107. South America Orphan Indication Treatment Sales by Type (2023-2028) & (K Units)
Table 108. South America Orphan Indication Treatment Sales by Application (2017-2022) & (K Units)
Table 109. South America Orphan Indication Treatment Sales by Application (2023-2028) & (K Units)
Table 110. Middle East & Africa Orphan Indication Treatment Sales by Region (2017-2022) & (K Units)
Table 111. Middle East & Africa Orphan Indication Treatment Sales by Region (2023-2028) & (K Units)
Table 112. Middle East & Africa Orphan Indication Treatment Revenue by Region (2017-2022) & (USD Million)
Table 113. Middle East & Africa Orphan Indication Treatment Revenue by Region (2023-2028) & (USD Million)
Table 114. Middle East & Africa Orphan Indication Treatment Sales by Type (2017-2022) & (K Units)
Table 115. Middle East & Africa Orphan Indication Treatment Sales by Type (2023-2028) & (K Units)
Table 116. Middle East & Africa Orphan Indication Treatment Sales by Application (2017-2022) & (K Units)
Table 117. Middle East & Africa Orphan Indication Treatment Sales by Application (2023-2028) & (K Units)
Table 118. Orphan Indication Treatment Raw Material
Table 119. Key Manufacturers of Orphan Indication Treatment Raw Materials
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Orphan Indication Treatment Typical Distributors
Table 123. Orphan Indication Treatment Typical Customers
List of Figures
Figure 1. Orphan Indication Treatment Picture
Figure 2. Global Orphan Indication Treatment Revenue Market Share by Type in 2021
Figure 3. Biologics
Figure 4. Non-Biologics
Figure 5. Global Orphan Indication Treatment Revenue Market Share by Application in 2021
Figure 6. Hospital Pharmacy
Figure 7. Retail Pharmacy
Figure 8. Online Sales
Figure 9. Global Orphan Indication Treatment Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Orphan Indication Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Orphan Indication Treatment Sales (2017-2028) & (K Units)
Figure 12. Global Orphan Indication Treatment Price (2017-2028) & (US$/Unit)
Figure 13. Global Orphan Indication Treatment Production Capacity (2017-2028) & (K Units)
Figure 14. Global Orphan Indication Treatment Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Orphan Indication Treatment Market Drivers
Figure 16. Orphan Indication Treatment Market Restraints
Figure 17. Orphan Indication Treatment Market Trends
Figure 18. Global Orphan Indication Treatment Sales Market Share by Manufacturer in 2021
Figure 19. Global Orphan Indication Treatment Revenue Market Share by Manufacturer in 2021
Figure 20. Orphan Indication Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Orphan Indication Treatment Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Orphan Indication Treatment Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Orphan Indication Treatment Sales Market Share by Region (2017-2028)
Figure 24. Global Orphan Indication Treatment Revenue Market Share by Region (2017-2028)
Figure 25. North America Orphan Indication Treatment Revenue (2017-2028) & (USD Million)
Figure 26. Europe Orphan Indication Treatment Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Orphan Indication Treatment Revenue (2017-2028) & (USD Million)
Figure 28. South America Orphan Indication Treatment Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Orphan Indication Treatment Revenue (2017-2028) & (USD Million)
Figure 30. Global Orphan Indication Treatment Sales Market Share by Type (2017-2028)
Figure 31. Global Orphan Indication Treatment Revenue Market Share by Type (2017-2028)
Figure 32. Global Orphan Indication Treatment Price by Type (2017-2028) & (US$/Unit)
Figure 33. Global Orphan Indication Treatment Sales Market Share by Application (2017-2028)
Figure 34. Global Orphan Indication Treatment Revenue Market Share by Application (2017-2028)
Figure 35. Global Orphan Indication Treatment Price by Application (2017-2028) & (US$/Unit)
Figure 36. North America Orphan Indication Treatment Sales Market Share by Type (2017-2028)
Figure 37. North America Orphan Indication Treatment Sales Market Share by Application (2017-2028)
Figure 38. North America Orphan Indication Treatment Sales Market Share by Country (2017-2028)
Figure 39. North America Orphan Indication Treatment Revenue Market Share by Country (2017-2028)
Figure 40. United States Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Orphan Indication Treatment Sales Market Share by Type (2017-2028)
Figure 44. Europe Orphan Indication Treatment Sales Market Share by Application (2017-2028)
Figure 45. Europe Orphan Indication Treatment Sales Market Share by Country (2017-2028)
Figure 46. Europe Orphan Indication Treatment Revenue Market Share by Country (2017-2028)
Figure 47. Germany Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Orphan Indication Treatment Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Orphan Indication Treatment Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Orphan Indication Treatment Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Orphan Indication Treatment Revenue Market Share by Region (2017-2028)
Figure 56. China Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Orphan Indication Treatment Sales Market Share by Type (2017-2028)
Figure 63. South America Orphan Indication Treatment Sales Market Share by Application (2017-2028)
Figure 64. South America Orphan Indication Treatment Sales Market Share by Country (2017-2028)
Figure 65. South America Orphan Indication Treatment Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Orphan Indication Treatment Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Orphan Indication Treatment Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Orphan Indication Treatment Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Orphan Indication Treatment Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Orphan Indication Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Orphan Indication Treatment in 2021
Figure 77. Manufacturing Process Analysis of Orphan Indication Treatment
Figure 78. Orphan Indication Treatment Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 希少疾病用医薬品の世界市場2023年：腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他
  • 世界の神経線維腫症治療薬市場2022年：市場規模予測（～2028年）
  • 世界の軟骨形成術治療薬市場2022年：市場規模予測（～2028年）
  • 世界のロキサピン市場2022年：市場規模予測（～2028年）
  • 世界のフラタキシンミトコンドリア市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19492 )"世界のオーファン疾患治療市場2022年：市場規模予測（～2028年）" (英文：Global Orphan Indication Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。